Diovan Clinical Trials

Browse 22 Diovan Medical Studies Across 49 Cities

4 Phase 3 Trial · 58 Diovan Clinics

Reviewed by Michael Gill, B. Sc.
10 Diovan Clinical Trials Near Me
Top Cities for Diovan Clinical Trials
Image of Rochester in Minnesota.
Rochester
2Active Trials
Mayo Clinic in RochesterTop Active Site
Image of Boston in Massachusetts.
Boston
2Active Trials
Massachusetts General HospitalTop Active Site
Diovan Clinical Trials by Phase of Trial
N/A Diovan Clinical Trials
2Active Diovan Clinical Trials
2Number of Unique Treatments
1Number of Active Locations
Most Recent Diovan Clinical Trials

Do you have high blood pressure, heart failure, or cardiomyopathy? One type of medicine that can help is known as an angiotensin II receptor blocker (ARB). This can keep your blood vessels from narrowing, which is dangerous since it restricts blood flow. As a result, the blood will flow better through those vessels .

Currently, Diovan has two uses - to treat high blood pressure, heart failure and cardiomyopathy. Its clinical name is Valsartan. Doctors also prescribe it to heart attack victims, since it could possibly help them to live longer afterward.

Diovan Clinical Trials first started in June 2012 and ended in January 2017. There were 127 participants.

What Are Diovan Clinical Trials?

There were three arms for this trial. One group got .25 mg/kg of Diovan and others got 4 mg/kg of a placebo. These trials were held over a six-week period for the first two arms and then 20 weeks for the third arm and the results were tallied. They checked things like Mean Diastolic Blood Pressure at the end of the six weeks and they also checked where these patients ranked in terms of their age, gender, and height, along with seeing if their Urine Albumin Creatine Percentage Ratio went down.

Why Is Diovan Being Studied In Clinical Trials?

High blood pressure, heart failure and cardio myopathy all are dangers to people around the world. The manufacturers were looking for things that could help people live a better quality of life if they had these conditions. They wanted to see how this medication would help lower the negative diagnostic numbers for these patients.

How Does Diovan Treatment Work?

People are supposed to take it once a day. It does not matter whether they take it without food, but they do need to make sure that they take it at the same time each day. Diovan can be made into a liquid for children who have trouble swallowing the tablet.

The main thing to be careful about is that women who are pregnant should not take this, since it poses a severe risk to the unborn baby. Do not breastfeed your baby if you are taking this, too. Also, diabetics who take medication that has aliskiren should avoid this.

If you have kidney issues, you should let your doctor know and if you are also on a low-salt diet, then you should tell your doctor.

What Are Some of the Breakthrough Clinical Trials Involving Diovan?

There was a clinical trial in Glasgow in August 2021 to determine if it could help with heart failure. It was a randomized study and the results will be likely made public at some point after October 2023.

Who Are The Key Opinion Leaders On Diovan Clinical Trial Research?

The Food and Drug Administration has approved Diovan to be used by children as young as 1 for hypertension.

Diovan is something that still shows promise in helping people with hypertension, heart failure or cardiomyopathy. The clinical trials showed that.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: September 2nd, 2023

References1 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9:CD013825. doi: 10.1002/14651858.CD013825.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/344733432 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. https://pubmed.ncbi.nlm.nih.gov/344733433 Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659. No abstract available. Erratum In: Circulation. 2020 Jan 14;141(2):e33. https://pubmed.ncbi.nlm.nih.gov/307001394 Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659. Erratum in: Circulation. 2020 Jan 14;141(2):e33. https://pubmed.ncbi.nlm.nih.gov/307001395 McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. https://pubmed.ncbi.nlm.nih.gov/251760156 Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090. https://pubmed.ncbi.nlm.nih.gov/304156017 Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum In: N Engl J Med. 2019 Mar 14;380(11):1090. https://pubmed.ncbi.nlm.nih.gov/304156018 Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1. https://pubmed.ncbi.nlm.nih.gov/314757949 Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1. https://pubmed.ncbi.nlm.nih.gov/3147579410 Arora P, Reingold J, Baggish A, Guanaga DP, Wu C, Ghorbani A, Song Y, Chen-Tournaux A, Khan AM, Tainsh LT, Buys ES, Williams JS, Heublein DM, Burnett JC, Semigran MJ, Bloch KD, Scherrer-Crosbie M, Newton-Cheh C, Kaplan LM, Wang TJ. Weight loss, saline loading, and the natriuretic peptide system. J Am Heart Assoc. 2015 Jan 16;4(1):e001265. doi: 10.1161/JAHA.114.001265. https://pubmed.ncbi.nlm.nih.gov/25595796